



Related MLN Matters Article #: MM3331

Date Posted: October 4, 2004

Related CR #: 3331

Billing Instructions for ADVATE rAHF-PFM on Medicare Claims

Key Words

CR3331, MM3331, ADVATE, rAHF-PFM

Provider Types Affected

Physicians, providers, and suppliers

Key Points

- The effective date for CR3331 is July 25, 2003; the implementation date is September 27, 2004.
- ADVATE rAHF-PFM was approved by the Food and Drug Administration (FDA) July 25, 2003.
- The payment limit for claims submitted for services from January 1, 2004 through December 31, 2004 for Advate is the same payment limit currently assigned to HCPCS code J7192.
- Effective for dates of service on or after July 25, 2003, Medicare FIs will reject claims for Advate if they do not use code J7192. These claims will be adjusted to reflect J7192 and carriers will append modifier "CC" to reflect this adjustment.
- Note: Advate is not subject to the 85% of the Average Wholesale Price (AWP) ruling on payment limits for most drugs and biologicals not paid on a cost or prospective payment basis for drugs and biologicals furnished on and after January 1, 2004.
- Advate is a blood clotting factor and, as such, has a payment limit of 95% of the AWP.

Important Links

MLN Matters CR transmittals for CR3331 (transmittal #112) MMA - Billing Instructions for ADVATE rAHF-PFM on Medicare Claims Revised: 10/4/2004

<http://www.cms.hhs.gov/transmittals/Downloads/R112OTN.pdf>

MLN Matters Article MM3331 - MMA - Billing Instructions for ADVATE rAHF-PFM on Medicare Claims Revised: 10/4/2004

<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM3331.pdf>